Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M46,311Revenue $M10,706Net Margin (%)16.6Altman Z-Score3.9
Enterprise Value $M46,311EPS $3.9Operating Margin %19.7Piotroski F-Score7
P/E(ttm)27.5Beneish M-Score-2.6Pre-tax Margin (%)17.7Higher ROA y-yY
Price/Book4.710-y EBITDA Growth Rate %7.3Quick Ratio1.4Cash flow > EarningsY
Price/Sales4.65-y EBITDA Growth Rate %2.0Current Ratio1.9Lower Leverage y-yY
Price/Free Cash Flow25.8y-y EBITDA Growth Rate %-2.6ROA % (ttm)8.7Higher Current Ratio y-yN
Dividend Yield %1.3PEG13.7ROE % (ttm)18.0Less Shares Outstanding y-yN
Payout Ratio %43.0Shares Outstanding M453ROIC % (ttm)15.0Gross Margin Increase y-yY

Gurus Latest Trades with COV

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
COVDavid Einhorn 2014-12-31 Buy 1.2%$82.2 - $104.06
($96)
$ 106.7111%New holding851,341
COVHOTCHKIS & WILEY 2014-12-31 Add0.07%$82.2 - $104.06
($96)
$ 106.7111%Add 28.50%935,100
COVMario Gabelli 2014-12-31 Reduce-0.05%$82.2 - $104.06
($96)
$ 106.7111%Reduce 22.30%359,176
COVJohn Paulson 2014-09-30 Add2%$82.54 - $91.76
($88.57)
$ 106.7120%Add 79.93%12,595,000
COVPrivate Capital 2014-09-30 Reduce-0.85%$82.54 - $91.76
($88.57)
$ 106.7120%Reduce 33.88%157,828
COVGeorge Soros 2014-09-30 Sold Out -0.15%$82.54 - $91.76
($88.57)
$ 106.7120%Sold Out0
COVMario Gabelli 2014-09-30 Reduce-0.08%$82.54 - $91.76
($88.57)
$ 106.7120%Reduce 27.49%462,251
COVJohn Paulson 2014-06-30 Buy 2.7%$69.03 - $91.24
($74.56)
$ 106.7143%New holding7,000,000
COVBill Nygren 2014-06-30 Reduce-1.51%$69.03 - $91.24
($74.56)
$ 106.7143%Reduce 94.09%160,000
COVRobert Olstein 2014-06-30 Sold Out -0.95%$69.03 - $91.24
($74.56)
$ 106.7143%Sold Out0
COVYacktman Focused Fund 2014-06-30 Sold Out -0.62%$69.03 - $91.24
($74.56)
$ 106.7143%Sold Out0
COVYacktman Fund 2014-06-30 Sold Out -0.56%$69.03 - $91.24
($74.56)
$ 106.7143%Sold Out0
COVDonald Yacktman 2014-06-30 Sold Out -0.55%$69.03 - $91.24
($74.56)
$ 106.7143%Sold Out0
COVGeorge Soros 2014-06-30 Buy 0.15%$69.03 - $91.24
($74.56)
$ 106.7143%New holding227,000
COVJoel Greenblatt 2014-06-30 Sold Out $69.03 - $91.24
($74.56)
$ 106.7143%Sold Out0
COVJoel Greenblatt 2014-03-31 Buy $66.35 - $72.5
($69.62)
$ 106.7153%New holding3,746
COVPrivate Capital 2013-12-31 Reduce-0.8%$59.82 - $68.42
($65.08)
$ 106.7164%Reduce 36.57%244,555
COVVanguard Health Care Fund 2013-12-31 Add0.22%$59.82 - $68.42
($65.08)
$ 106.7164%Add 24.79%4,994,700
COVHOTCHKIS & WILEY 2013-12-31 Reduce-0.16%$59.82 - $68.42
($65.08)
$ 106.7164%Reduce 46.79%657,000
COVJohn Keeley 2013-12-31 Reduce-0.06%$59.82 - $68.42
($65.08)
$ 106.7164%Reduce 52.66%44,520
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

COV is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


COV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sgrignari MichaelSenior Vice President 2014-12-05Sell25,795$103.483.12view
REILLEY DENNIS HDirector 2014-12-03Sell10,521$101.395.25view
Tarnoff Michael EVice President 2014-12-01Sell8,000$100.995.66view
BROWN RICHARD G JRVice President and Controller 2014-11-17Buy5,300$94.4412.99view
Lannum Coleman N IIIVice President 2014-11-14Buy821$93.5314.09view
Clemmer James CSenior Vice President 2014-11-10Sell3,464$92.4815.39view
BRUST ROBERT HDirector 2014-11-07Sell4,000$92.0315.95view
Lannum Coleman N IIIVice President 2014-08-27Buy3,338$87.2322.33view
Lannum Coleman N IIIVice President 2014-08-26Buy1,736$87.4622.01view
Lannum Coleman N IIIVice President 2014-08-19Buy1,720$87.8221.51view

Quarterly/Annual Reports about COV:

News about COV:

Articles On GuruFocus.com
Mairs & Power Balanced Fund Q4 2014 Commentary Mar 31 2015 
Weekly 52-Week Highs Highlight: KR, COV, VRX, NOC Feb 01 2015 
Dravid Abrams and His Top Four Stock Picks Jan 27 2015 
Johnson & Johnson Riding High On Ebola Vaccines Jan 21 2015 
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
Dividend Aristocrats In Focus Part 44: Medtronic Nov 23 2014 
Third Avenue's Top Stocks as of Q3 Nov 16 2014 
Medical Technology Company Offers Investment Opportunity Sep 25 2014 
Gabelli Value 25 Fund Second Quarter Commentary Sep 15 2014 
Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 

More From Other Websites
Medtronic Revenue Boosted by Covidien Acquisition Sep 03 2015
Medtronic sales surge as rise in U.S. surgeries drives demand Sep 03 2015
Medtronic Beats on Q1 Earnings, Covidien Synergy on Track Sep 03 2015
Covidien deal, heart devices boost Medtronic's fortunes Sep 03 2015
Medtronic (MDT) Stock Rallies as Earnings Exceed Estimates, Jim Cramer Weighs In Sep 03 2015
Medtronic Profit Beats Estimates on New Heart Device Demand Sep 03 2015
Medtronic Results to Provide Checkup on Covidien Deal Sep 02 2015
Medtronic Rises Ahead Of Earnings On Higher Target Sep 02 2015
Will Currency Woes Weigh on Medtronic (MDT) Q1 Earnings? Aug 31 2015
J&J gets partial win against Covidien in surgical patent case Aug 07 2015
Johnson & Johnson gets partial win in patent appeal against Covidien Aug 07 2015
Covidien agrees to settle some cases over transvaginal mesh devices Jun 24 2015
Medtronic (MDT) Earnings Report: Q4 2015 Conference Call Transcript Jun 02 2015
Where Medtronic makes its money after the Covidien acquisition Jun 02 2015
Medtronic Posts Strong Q4 with Earnings, Revenue Beat - Analyst Blog Jun 02 2015
Medtronic Profit Beats Estimates After Covidien Purchase Jun 02 2015
Medtronic (MDT) Likely to Outshine Q4 Earnings Estimates - Analyst Blog Jun 01 2015
Medtronic (MDT) Reveals Impressive Preliminary Q4 Results - Analyst Blog May 20 2015
Medtronic Sales Beat Analysts’ Estimates After Covidien Deal May 19 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK